Company: INTS
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001567264-25-000103
Chunk: 73

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 73
---
)General and administrative1,180 1,419 (239)3,549 4,853 (1,304)Total operating expenses2,733 3,570 (837)8,832 13,382 (4,550)Loss from operations(2,733)(3,570)837 (8,832)(13,382)4,550 Interest income59 48 11 92 286 (194)Other income, net3 9 (6)185 9 176 Net loss$(2,671)$(3,513)$842 $(8,555)$(13,087)$4,532 

Three Months Ended September 30,Nine Months Ended September 30,20252024Change20252024ChangeResearch and development expenses:Clinical trial expenses:IT-01 Study (Phase 1/2 Metastatic Cancers)$— $53 $(53)$— $114 $(114)INVINCIBLE-2 Study (Phase 2 Breast)— 12 (12)— 233 (233)INVINCIBLE-3 Study (Phase 3 Sarcoma)883 1,225 (342)3,267 4,613 (1,346)INVINCIBLE-4 Study (Phase 2 Breast)126 108 18 323 424 (101)Other— — — 14 58 (44)Clinical trial expenses1,009 1,398 (389)3,604 5,442 (1,838)Contract manufacturing30 20 10 59 651 (592)Salaries and benefits related costs303 497 (194)925 1,340 (415)Consulting & Other29 49 (20)90 126 (36)Stock-based compensation182 187 (5)605 970 (365)Total research and development expenses$1,553 $2,151 $(598)$5,283 $8,529 $(3,246)

Three Months Ended September 30,Nine Months Ended September 30,20252024Change20252024ChangeGeneral and administrative expenses:Salaries and benefits related costs$225 $325 $(100)$688 $949 $(261)Legal fees130 113 17 371 545 (174)Audit fees72 113 (41)237